Mainstay Medical eyeing late 2020 US commercialisation approval

Irish medical device firm Mainstay Medical is expecting, by the end of next year, a decision on whether its treatment for chronic back pain will be commercially approved for sale in the US.

Mainstay's sole product - already commercially available in Ireland, the UK and most notably Germany - is an implantable device called ReActiv8, which can be activated twice a day to treat the condition.